Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates.
Ovid Therapeutics Inc. (OVID)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,500,968 | $28,247,604 | -2% | 0.25% |
| 2. | ADAR1 Capital Management Daniel Schneeberger | 7,417,479 | $19,953,019 | +64% | 0.91% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 6,719,076 | $18,074,314 | +22% | 0.02% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 6,163,781 | $16,580,571 | 0.02% | |
| 5. | Braidwell LP Alex Karnal | 5,919,464 | $15,923,358 | 0.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.73 | 6,810 | $4,971.30 | 34,935 | 2025-01-27 | Filing | |
| $2.76 | 18,248 | $50,364.48 | 3,616,715 | 2024-03-18 | Filing | |
| $5.84 | 8,488 | $49,569.92 | 5,792,530 | 2020-08-28 | Filing | |
| $2.50 | 2,000,000 | $5,000,000.00 | 5,750,000 | 2019-10-08 | Filing | |
| $2.50 | 60,000 | $150,000.00 | 4,736,529 | 2019-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.45 | 11,656 | $16,901.20 | 61,750 | 2026-02-23 | Filing | |
| $1.45 | 8,541 | $12,384.45 | 88,188 | 2026-02-23 | Filing | |
| $0.56 | 5,279 | $2,956.24 | 73,406 | 2025-02-26 | Filing | |
| $0.56 | 3,902 | $2,185.12 | 67,973 | 2025-02-26 | Filing | |
| $2.15 | 17,344 | $37,289.60 | 0 | 2022-09-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,741,234 | $55,897,626 | 0.02% | |
| 2. | 11,812,241 | $31,774,928 | 0.42% | |
| 3. | 10,823,480 | $29,115,162 | 0% | |
| 4. | 10,144,562 | $27,288,872 | 1.23% | |
| 5. | 7,900,765 | $21,253,058 | 0% |
News See All
10 Fastest Growing Tech Penny Stocks to Buy
In this article, we will look at the 10 Fastest Growing Tech Penny Stocks to Buy.
8 Best Fast Growing Penny Stocks to Buy Right Now
In this article, we will discuss the 8 Best Fast Growing Penny Stocks to Buy Right Now.
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best fast growing penny stocks to buy according to analysts.
7 Best Fast Growing Penny Stocks to Buy According to Analysts
On January 14, Lale Akoner, global market analyst at eToro, appeared on CNBC to state that 2026 is driven by rotation into small caps and advised diversification.
B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target
Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc.
8 Best US Stocks Under $10 to Invest in
In this article, we will take a look at some of the best US stocks under $10 to invest in.
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB.
Hedge Fund Resource Center